Beirne Wealth Consulting Services LLC Increases Position in Novavax, Inc. (NASDAQ:NVAX)

Beirne Wealth Consulting Services LLC grew its holdings in Novavax, Inc. (NASDAQ:NVAX) by 65.0% during the fourth quarter, HoldingsChannel reports. The firm owned 16,500 shares of the biopharmaceutical company’s stock after acquiring an additional 6,500 shares during the period. Beirne Wealth Consulting Services LLC’s holdings in Novavax were worth $133,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. State Street Corp lifted its position in Novavax by 26.7% during the third quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company’s stock worth $97,099,000 after buying an additional 1,621,772 shares in the last quarter. Shah Capital Management raised its holdings in shares of Novavax by 13.6% during the 4th quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company’s stock worth $89,637,000 after acquiring an additional 1,333,305 shares during the period. Two Sigma Advisers LP boosted its position in shares of Novavax by 48.9% during the 3rd quarter. Two Sigma Advisers LP now owns 1,999,400 shares of the biopharmaceutical company’s stock valued at $25,252,000 after acquiring an additional 656,900 shares during the last quarter. Bank of Montreal Can grew its stake in shares of Novavax by 26.7% in the 3rd quarter. Bank of Montreal Can now owns 2,454,325 shares of the biopharmaceutical company’s stock valued at $32,643,000 after buying an additional 517,727 shares during the period. Finally, Geode Capital Management LLC grew its position in Novavax by 9.5% in the third quarter. Geode Capital Management LLC now owns 3,502,489 shares of the biopharmaceutical company’s stock worth $44,245,000 after acquiring an additional 304,159 shares during the period. 53.04% of the stock is currently owned by hedge funds and other institutional investors.

Novavax Trading Up 0.7 %

Shares of NASDAQ:NVAX opened at $8.25 on Wednesday. Novavax, Inc. has a 1 year low of $3.81 and a 1 year high of $23.86. The firm’s 50-day moving average is $8.72 and its two-hundred day moving average is $10.20.

Insider Buying and Selling

In related news, Director James F. Young sold 5,400 shares of the business’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total transaction of $43,200.00. Following the completion of the transaction, the director now directly owns 51,760 shares of the company’s stock, valued at $414,080. The trade was a 9.45 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Rachel K. King sold 4,150 shares of the stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $9.02, for a total value of $37,433.00. Following the completion of the sale, the director now directly owns 14,770 shares in the company, valued at $133,225.40. This represents a 21.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 14,150 shares of company stock valued at $119,641 in the last ninety days. Company insiders own 1.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $19.00 price objective on shares of Novavax in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, Novavax presently has an average rating of “Hold” and an average price target of $17.83.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.